Bone mineral density as a surrogate biomarker for fracture risk reduction

Affiliations

¹ Federal University of Rio Grande do Norte, Endocrinology Unit, Natal, Brazil. Electronic address: ufrn01337@ufrn.edu.br.
² Federal University of Rio Grande do Norte, Endocrinology Unit, Natal, Brazil.

Comment

Josivan G Lima et al. Lancet Diabetes Endocrinol. 2020 Nov.

. 2020 Nov;8(11):875-876.

doi: 10.1016/S2213-8587(20)30339-9.

¹ Federal University of Rio Grande do Norte, Endocrinology Unit, Natal, Brazil. Electronic address: ufrn01337@ufrn.edu.br.
² Federal University of Rio Grande do Norte, Endocrinology Unit, Natal, Brazil.

No abstract available

Comment in

Bone mineral density as a surrogate biomarker for fracture risk reduction - Authors' reply.
Black DM, Bouxsein ML, Bauer DC, Eastell R. Black DM, et al. Lancet Diabetes Endocrinol. 2020 Nov;8(11):876. doi: 10.1016/S2213-8587(20)30340-5. Lancet Diabetes Endocrinol. 2020. PMID: 33065056 No abstract available.

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials.
Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, Khosla S, de Papp A, Mitlak B, Cauley JA, McCulloch CE, Eastell R, Bouxsein ML; Foundation for the National Institutes of Health Bone Quality Project. Black DM, et al. Lancet Diabetes Endocrinol. 2020 Aug;8(8):672-682. doi: 10.1016/S2213-8587(20)30159-5. Lancet Diabetes Endocrinol. 2020. PMID: 32707115